Heat Biologics Inc HTBX shares traded sharply higher after the circulation of a document from the World Intellectual Property Organization's PatentScope highlighting lung cancer treatment.
The document circulated is a patent granted for “GP96-based cancer therapy” by Heat Biologics and contains the following:
"The present disclosure relates, inter alia, to compositions and methods for treating cancer, including lung cancer (e.g., Non-Small Cell Lung Cancer), comprising administering (a) a cell harboring an expression vector comprising a nucleotide sequence that encodes a secretable vaccine protein and (b) an immune checkpoint inhibitor to a subject in need thereof."
Heat Biologics traded up 18 percent to 85 cents per share at time of publication Friday afternoon.
Related Links:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.